Tag: seizures

  • CBD Oil Quickly Becoming Popular Opioid Alternative

    CBD Oil Quickly Becoming Popular Opioid Alternative

    One expert says CBD oil sales are growing nationally, particularly in states that allow medical marijuana but not recreational.

    When it comes to pain management, there may be a safer alternative to prescription pain medication: CBD oil, also known as cannabidiol.

    In Georgia, according to WSB-TV Atlanta, the hemp-derived CBD product is legal because it only contains trace amounts of THC, the active ingredient in marijuana.

    CBD oil is sold at Little Five Points Pharmacy in northeast Atlanta, and pharmacist Ira Katz tells WSB-TV that it has been effective for some of his patients. 

    “We know that this can reduce pain,” he said. “I have several patients that we’ve been putting this on, recommending this to them, and it’s great. It helps. It makes a big difference.”

    The oil does not give users a high. “People are turning to cannabidiol as an alternative when they can’t get low THC oil,” Anthony LaBorde, store operator for Discount Nutrition in Midtown Atlanta and Acworth, told the Atlanta Journal-Constitution. “We get people coming in here who say, ‘Oh my gosh, this is marijuana, I can’t believe you sell this.’ There’s complete confusion.”

    Studies have found that CBD oil is effective for treating neuropathic pain, arthritis pain, anxiety, sleep disorders and depression.

    “I’ve had some patients that have been able to get off some of those pain medications, which they hated taking,” Katz told WSB-TV. “It has no addictive properties and far less side effects than do a lot of the prescription pain medications.”

    According to Bethany Gomez, research director for the Chicago-based Brightfield Group, sales of CBD are growing across the nation, particularly in states like Georgia that have some form of a medical marijuana program, but do not allow cannabis for adult use. In 2016, the market for the product was $174 million, compared to $590 million this year. 

    “CBD is very widely used by people who would not come anywhere near cannabis, who don’t want anything to do with the mind-altering effects of marijuana but want treatment for chronic pain, anxiety and women’s health conditions,” Gomez told the Journal-Constitution.

    Despite the apparent benefits, CBD oil still concerns some local law enforcement officials. Wesley Nunn, president of the Georgia Narcotics Officers Association and commander of the Ocmulgee Drug Task Force, fears shops may be disguising THC oil as CBD oil, the difference lying in the potency of the product. 

    “You don’t know what’s in it. That’s the problem,” Nunn told the Journal-Constitution. “If it’s helping with seizures, appetite disorders and PTSD, let’s get it regulated… There’s so much money being pushed behind the marijuana trade, and people are trying to get on board.”

    View the original article at thefix.com

  • FDA Approves First Cannabis-Based Drug For Debilitating Seizures

    FDA Approves First Cannabis-Based Drug For Debilitating Seizures

    The DEA must re-classify cannabidiol (CBD) before the medication can be available to patients.

    On Monday, the Food and Drug Administration (FDA) approved Epidiolex, a cannabidiol (CBD) treatment for debilitating epilepsy beginning in children as young as 1 or even younger.

    Cannabidiol is a chemical compound (cannabinoid) of the cannabis plant known for its pain-relieving and anti-seizure properties, among others. However, it differs from THC, another cannabinoid, by not producing the “high” that marijuana is known for.

    Epidiolex was approved for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, both characterized by frequent and debilitating seizures that severely delay or limit a child’s development.

    Lennox-Gastaut syndrome can appear in children as young as 3-5 years old, while Dravet syndrome appears during infancy.

    According to STAT News, Epidiolex was shown to reduce the number of seizures by about 40% in patients with either disorder.

    “The FDA is committed to this kind of careful scientific research and drug development,” FDA Commissioner Scott Gottlieb said in a statement. “Controlled clinical trials testing the safety and efficacy of a drug, along with careful review through the FDA’s drug approval process, is the most appropriate way to bring marijuana-derived treatments to patients.”

    However, drug maker GW Pharmaceuticals will have to wait until the Drug Enforcement Administration (DEA) decides whether to re-classify cannabidiol before it can be available to patients.

    Currently CBD is classified as a Schedule I drug, meaning that, by the federal government’s definition, it has no medical value and a high potential for abuse. STAT News reports that the DEA will make a decision in the next 90 days.

    Drugs that mimic the anti-nausea and appetite-inducing properties of THC have long been FDA-approved for treating chemotherapy patients and HIV/AIDS patients.

    Over a dozen U.S. states have passed legislation specifically to allow CBD for debilitating epilepsy, many of them to help children.

    The FDA’s decision gives hope to families living in non-medical marijuana states who have struggled to legally obtain and use CBD products for these conditions.

    Alexis Bortell is one patient who could have benefited from legal CBD in all 50 states.

    Bortell made headlines last year for being the 12-year-old girl who sued Attorney General Jeff Sessions for promoting the anti-marijuana policy that made it difficult for her to treat her intractable epilepsy that she’s suffered since she was 7 years old.

    Her family ultimately moved from Texas to Colorado—where cannabis is legal for both medical and adult use—so they could legally access CBD medication, which she says has allowed her to be seizure-free for about three years now.

    View the original article at thefix.com